| AI for Good: AI is speeding up drug development |
Source: ChatGPT 4o |
| AI is helping pharmaceutical researchers find new treatments faster and cheaper by surfacing promising compounds buried deep in massive datasets. Dotmatics, a R&D software company, recently acquired by Siemens for $5.1B, is applying AI to identify potential drug candidates in a fraction of the time it used to take. |
| Phil Mounteney, VP of Science and Technology at Dotmatics, explains it like this: “The art of drug discovery is really finding drugs in these massive haystacks of data. AI is like a supercharged magnet that helps us sort through those haystacks and find the needle way more efficiently than before.” |
| Why it matters: Drug development is notoriously long and expensive. It can take up to 10 years and cost between $2 and $6 billion to bring a single drug to market. Of that, roughly six years are spent on early discovery—just identifying the compound that might work. Dotmatics is using AI to cut that phase down to as little as two years. |
| Faster discovery means earlier trials, quicker regulatory paths and lower costs for companies and patients alike. The company believes that AI could reduce the full research and clinical timeline by as much as 50 percent. |
| How it works: Dotmatics combines AI with scientific data platforms to accelerate each step of the R&D process: |
| It scans huge chemical libraries to identify overlooked or repurposable compounds.It models how drug candidates interact with target proteins or diseases.It automates lab workflows that used to take researchers weeks.It pulls from historic datasets to inform present-day projects. |
| Mounteney says AI played a key role in accelerating the COVID mRNA vaccine rollout by leveraging years of stored research and rapidly analyzing it to guide development. |
| Big picture: Drug discovery may be one of the most direct ways AI can improve human health. Tools like Dotmatics are not replacing scientists but instead giving them the speed and precision to find answers faster. With over $300 million in projected revenue for 2025, the company is betting that faster cures can also mean a stronger business case. |
-
Archives
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- January 2015
-
Meta
Source: ChatGPT 4o